Palisade Asset Management’s Novavax NVAX Stock Holding History

Palisade Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50	Closed	-$434	–	511
2025 Q3	$434	Buy	+50	New	+$389	﹤0.01%	577

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Palisade Asset Management's NVAX Position: Q4 2025 in Review

Palisade Asset Management sold out of Novavax (NVAX) in Q4 2025, closing a stake of 50 shares — an estimated $434 sold.

Palisade Asset Management first reported a position in NVAX in Q3 2025 and held it in 1 quarter. The position peaked at $434 in Q3 2025. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2025.

Palisade Asset Management reported no remaining Novavax position as of Q4 2025 after selling out during the quarter.
Palisade Asset Management sold 50 Novavax shares in Q4 2025, an estimated $434.
Palisade Asset Management first reported a position in Novavax in Q3 2025 and held it in 1 quarter.
Palisade Asset Management's Novavax position peaked at $434 in Q3 2025.
235 funds tracked by Wall St. Rank held Novavax as of Q4 2025.

Based on Palisade Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.